(VIANEWS) – LNA SANTE (LNA.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| LNA SANTE (LNA.PA) | €20.45 | 2.31% | 7.98% |
| TUBIZE-FIN (TUB.BR) | €96.80 | 1% | 4.97% |
| SARTORIUS STED BIO (DIM.PA) | €264.30 | 0.35% | 8.15% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. LNA SANTE (LNA.PA)
2.31% Forward Dividend Yield and 7.98% Return On Equity
LNA Santé SA engages in the management and operation of health establishments. The company operates retirement homes, medical and rehabilitation care, home hospital, surgery, mental health clinic, and health center. LNA Santé SA was founded in 1990 and is based in Vertou, France.
Earnings Per Share
As for profitability, LNA SANTE has a trailing twelve months EPS of €2.28.
PE Ratio
LNA SANTE has a trailing twelve months price to earnings ratio of 8.97. Meaning, the purchaser of the share is investing €8.97 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.98%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.1%, now sitting on 736.08M for the twelve trailing months.
More news about LNA SANTE.
2. TUBIZE-FIN (TUB.BR)
1% Forward Dividend Yield and 4.97% Return On Equity
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. The company was incorporated in 1928 and is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €1.98.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 48.89. Meaning, the purchaser of the share is investing €48.89 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.97%.
Volatility
TUBIZE-FIN’s last week, last month’s, and last quarter’s current intraday variation average was 0.79%, 0.32%, and 1.33%.
TUBIZE-FIN’s highest amplitude of average volatility was 0.84% (last week), 1.05% (last month), and 1.33% (last quarter).
Yearly Top and Bottom Value
TUBIZE-FIN’s stock is valued at €96.80 at 02:30 EST, under its 52-week high of €97.40 and way higher than its 52-week low of €60.80.
More news about TUBIZE-FIN.
3. SARTORIUS STED BIO (DIM.PA)
0.35% Forward Dividend Yield and 8.15% Return On Equity
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €3.36.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 78.66. Meaning, the purchaser of the share is investing €78.66 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.15%.
Sales Growth
SARTORIUS STED BIO’s sales growth for the next quarter is 12.2%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Apr 2, 2024, the estimated forward annual dividend rate is 0.69 and the estimated forward annual dividend yield is 0.35%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 8.2%, now sitting on 2.72B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is a negative 10.9% and positive 44.7% for the next.
More news about SARTORIUS STED BIO.
